- Home
- RDCM vs TIL Comparison
RDCM vs TIL Comparison
Compare RDCM & TIL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- RDCM
- TIL
- Stock Information
- Founded
- RDCM 1985
- TIL 2018
- Country
- RDCM Israel
- TIL United States
- Employees
- RDCM N/A
- TIL N/A
- Industry
- RDCM Computer peripheral equipment
- TIL Biotechnology: Pharmaceutical Preparations
- Sector
- RDCM Technology
- TIL Health Care
- Exchange
- RDCM Nasdaq
- TIL Nasdaq
- Market Cap
- RDCM 179.7M
- TIL 171.7M
- IPO Year
- RDCM 1997
- TIL 2021
- Fundamental
- Price
- RDCM $11.28
- TIL $15.46
- Analyst Decision
- RDCM Strong Buy
- TIL Buy
- Analyst Count
- RDCM 2
- TIL 5
- Target Price
- RDCM $15.00
- TIL $114.00
- AVG Volume (30 Days)
- RDCM 26.7K
- TIL 78.2K
- Earning Date
- RDCM 05-14-2025
- TIL 05-09-2025
- Dividend Yield
- RDCM N/A
- TIL N/A
- EPS Growth
- RDCM 79.17
- TIL N/A
- EPS
- RDCM 0.43
- TIL N/A
- Revenue
- RDCM $61,009,000.00
- TIL N/A
- Revenue This Year
- RDCM $14.93
- TIL N/A
- Revenue Next Year
- RDCM $10.74
- TIL N/A
- P/E Ratio
- RDCM $26.23
- TIL N/A
- Revenue Growth
- RDCM 18.23
- TIL N/A
- 52 Week Low
- RDCM $8.52
- TIL $9.62
- 52 Week High
- RDCM $15.98
- TIL $92.00
- Technical
- Relative Strength Index (RSI)
- RDCM 47.85
- TIL 44.19
- Support Level
- RDCM $9.88
- TIL $14.96
- Resistance Level
- RDCM $11.34
- TIL $18.71
- Average True Range (ATR)
- RDCM 0.66
- TIL 1.80
- MACD
- RDCM 0.04
- TIL 0.09
- Stochastic Oscillator
- RDCM 68.97
- TIL 46.32
About RDCM Radcom Ltd.
Radcom Ltd Ltd is engaged in providing network intelligence, 5G ready cloud-native, network intelligence solutions for telecom operators transitioning to 5G. The company has a network intelligence solution for 5G namely Radcom ACE. Its products consist of Radcom Network Visibility, Radcom Service Assurance, and Radcom Network Insights. It has offices in Israel, the United States, Brazil, and India. Key revenue is derived from sales in North America.
About TIL Instil Bio Inc.
Instil Bio Inc is a clinical-stage biopharmaceutical company focused on developing a cell therapy pipeline of autologous tumor infiltrating lymphocyte, or TIL, therapies for the treatment of patients with cancer. It is also engaged in developing a novel class of genetically engineered TIL therapies using its Co-Stimulatory Antigen Receptor, or CoStAR, platform. Its pipeline includes ITIL-306 which expresses a CoStAR molecule designed to recognize FRα, a tumor-associated antigen that is expressed on numerous solid tumors, including ovarian cancer, uterine cancer, NSCLC, and renal cancer.